Clinical trials
Uterine Cervical Neoplasms trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 9 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 13 |
| Active, not recruiting | 6 |
| Terminated | 5 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 5 |
| Merck Sharp & Dohme LLC | 5 |
| AstraZeneca | 3 |
| Daiichi Sankyo | 2 |
| EMD Serono Research & Development Institute, Inc. | 2 |
| Genmab | 2 |
| Haruhiko Fukuda | 2 |
| Pfizer | 2 |
| Seagen, a wholly owned subsidiary of Pfizer | 2 |
| Alterome Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Cervical Neoplasms | 46 |
| Ovarian Neoplasms | 18 |
| Endometrial Neoplasms | 16 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Squamous Cell Carcinoma of Head and Neck | 12 |
| Triple Negative Breast Neoplasms | 11 |
| Breast Neoplasms | 10 |
| Esophageal Neoplasms | 8 |
| Stomach Neoplasms | 8 |
| Urinary Bladder Neoplasms | 7 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.